PW Medtech Group (FRA:PWE) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PWE PW Medtech Group Ltd FRA:PWE
82 GF Score
Price €0.09
GF Value €0.14
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is PW Medtech Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

PW Medtech Group Quality Rank Related Terms

FRA:PWE
82GF Score
PW Medtech Group Ltd FRA:PWE
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PW Medtech Group (FRA:PWE) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of €0.09 is trading 36.1% below its estimated GF Value™ of €0.14. GuruFocus considers PW Medtech Group to be Significantly Undervalued.

Key valuation signals for FRA:PWE:

  • Quality Rank:
  • GF Value™: €0.14 vs. price of €0.09 (36.1% below fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PW Medtech Group Business Description

Other Exchanges 01358:Hong Kong
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score

Get the complete analysis for FRA:PWE

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.14
GF Value